Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|March 16, 2017
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetesTim Heise, Marianne Nørskov, Leszek Nosek, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 19, 2015
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargineTim Heise, Ulrike Hövelmann, Leszek Nosek, et al.
Diabetes, Obesity & Metabolism|June 22, 2016
Euglycaemic glucose clamp: what it can and cannot do, and how to do itTim Heise, Eric Zijlstra, Leszek Nosek, et al.
Journal of Diabetes Science and Technology|February 20, 2010
Continuous glucose monitoring during exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusionChristoph Kapitza, Ulrike Hövelmann, Leszek Nosek, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 22, 2006
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp studyKlaus Rave, Leszek Nosek, John Posner, et al.
The British Journal of Nutrition|March 10, 2010
Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose)Ines Holub, Andrea Gostner, Stephan Theis, et al.
Clinical Drug Investigation|February 11, 2017
Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection RegionsUlrike Hövelmann, Tim Heise, Leszek Nosek, et al.
Diabetes|May 27, 2004
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetesTim Heise, Leszek Nosek, Birgitte Biilmann Rønn, et al.
Clinical Pharmacokinetics|November 24, 2016
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes MellitusTim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann, et al.
Diabetes, Obesity & Metabolism|December 18, 2016
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetesChristoph Kapitza, Irene Nowotny, Anne Lehmann, et al.
Pageof 3